SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is spiking as the continued closure of the Strait of Hormuz and subsequent Middle East production cuts drive crude oil prices sharply higher, leading to widespread community debate on whether a parabolic surge to $150+ or a swift crash from potential strategic reserve releases is imminent.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending after resolving its legal dispute with Novo Nordisk and partnering to offer FDA-approved GLP-1 weight-loss medications on its platform, eliminating a significant bear thesis. This development has ignited strong bullish sentiment, with the community actively discussing a potential short squeeze due to high short interest and anticipating analyst upgrades.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Disney is trending following a Q1 earnings beat with record theme park revenue and improved streaming profitability, alongside the announcement of Josh D'Amaro as the new CEO; however, community sentiment remains divided, balancing strong fundamentals and a share buyback against lingering concerns over content strategy, linear TV pressures, and the company's aggressive stance on AI IP infringement.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

The community is actively discussing FuelCell Energy's potential in the surging AI data center market, following its Q1 revenue growth and a strategic collaboration targeting 450 MW for power solutions; however, many remain skeptical of management's ability to convert pipeline opportunities into definitive contracts amidst ongoing share dilution.

Aureus Greenway Holdings, Inc. engages in the ownership and operation of public golf country clubs, namely Kissimmee Bay Country Club and Remington Golf Club. It operates through the following segments: Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental, Membership Dues, Food and Beverage Services, and Ancillary Services and Amenities. The Golf Recreation, Retail Golf Products, and Equipment and Facilities Rental segment is involved in the collection of fees for every round of eighteen holes, provision of driving ranges for practice, sale of golf apparel and equipment, and rental of golf products and cars. The Membership Dues segment refers to the membership fees for customers to access the club's facilities and services for a set period or daily at the point of sale. The Food and Beverage Services segment provides culinary services such as catering. The Ancillary Services and Amenities segment offers leisure activities hosted in an on-premises clubhouse, kitchen, bar, and dining area. The company was founded on December 22, 2023 and is headquartered in Kissimmee, FL.

Aureus Greenway Holdings Inc.

Aureus Greenway Holdings (AGH) is trending due to its announced merger with Powerus, a drone startup backed by Eric Trump and Donald Trump Jr., with the community actively discussing its transformation into a defense-drone company poised for potential government contracts within the rapidly expanding drone sector.

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Relmada Therapeutics Inc

Relmada Therapeutics is gaining attention following positive 12-month Phase 2 interim data for its NDV-01 bladder cancer drug and a significant $160 million private placement, with the community split between bullish sentiment over the drug's potential and concerns about dilution and historical challenges.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

American Airlines is trending amidst escalating Middle East tensions, which are driving surging jet fuel costs and widespread flight cancellations, leading to predominantly bearish community discussions about potential further price declines for the airline sector despite its recent positive guidance.

ProShares Trust - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

SCO is trending as traders anticipate a sharp reversal in crude oil prices, which have seen extreme volatility amid escalating Middle East geopolitical tensions and concerns over the Strait of Hormuz. The community is actively buying into this inverse ETF, betting that oil's fear-driven rally is overblown and that prices will inevitably fall, though some debate the ETF's tracking and risk of a reverse split.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd. is trending amid sharply rising crude oil prices driven by escalating Middle East tensions, leading to intense debate among investors over its potential for a major short squeeze versus ongoing concerns about market manipulation.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as escalating geopolitical tensions, particularly involving the Middle East and surging oil prices, fuel intense community speculation about an impending market correction and heightened volatility. Traders are actively buying the leveraged ETF, anticipating a significant VIX spike, though concerns over market manipulation and its inherent decay remain key discussion points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Los Angeles-based eXoZymes Inc. (NASDAQ: $EXOZ), a pioneer of AI-enhanced enzymes that transform sustainable feedstock into nutraceuticals and new medicines, reported detailed downstream performance results from its recently completed 100-liter pilot production run of N-trans-caffeoyltyramine (NCT). 
 
eXoZymes Inc. is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1. 
 
The company reports that the pilot run achieved approximately 99% reaction conversion, 91% process recovery, and a 90% isolated yield, resulting in 535 grams of isolated NCT at 99.6% pharma-grade purity. The production was executed by external partner Cayman Chemical, marking the first time the exozyme-based biomanufacturing process has been run end-to-end by an external partner, demonstrating protocol transferability and operational robustness. 
 
Co-founder of eXoZymes and VP of Development, Paul Opgenorth, PhD, noted: “What makes this initial NCT pilot run profound is how counter to conventional experience these results are. In most biological systems, performance typically degrades as you scale - reactions become harder to control, yields drop, and variability increases. With our AI-enhanced enzymes - exozymes - we see the opposite trend. At very small laboratory scale, where cell-free reactions are usually developed and optimized, performance can actually be the weakest. It improves at the one-liter scale, and this scaled run at 100 liters further reinforces that the system benefits from operating at larger volumes. Seeing that behavior carry through to high recovery, isolated yield, and pharma-grade purity supports that exozymes represent a fundamentally different and more scalable biomanufacturing paradigm compared to existing approaches.” 
 
Read the full news release at: https://exozymes.com/blog/nct-pilot-run-details 
 
eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. 
 
To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor. 
 
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

David Shapiro

Brian Cheek

Brogley Panzarella

Ball Terjova

Allie Walker

Bana Daerhova

Refugio Bergstrom

Cal Dwan

James

Tyree

Julio

Edward

Dwight

top moon

Mangine Mckelvy

Pablo Rodriguez

Craig Salinas

Eugene Davenport

Michael Musto

Henry Callaghan

John Park

Jeanne Hodges

Kelly Distaffen

Renee Blankenship

Nina Studdard

Filomena Marsh

Ariana Storck

eXoZymes Inc. management brings together biotechnology and commercial expertise. The team combines scientific leadership from UCLA with business executives experienced in scaling technology companies, leveraging deep knowledge in enzyme engineering, artificial intelligence, and biomanufacturing to develop and commercialize cell-free production solutions for partners worldwide The eXoZymes Inc.

B2idigital

Exozymes Profile on B2i Digital

EXOZ reported detailed downstream performance results from its recently completed 100-liter pilot production run of NCT. The results expand upon the previously announced 100× scale-up milestone and provide new data demonstrating manufacturability, material recovery, and product quality at commercially relevant scale.

Exozymes

eXoZymes advancing commercial readiness with profound production metrics on initial NCT pilot run

Home

Investor

Disclaimer - Content is provided "as is" by companies featured on the site. Conduct a trusted advisory before making investments.

Disclaimer - Consult and advisor before making any investments

StockTwits Web

eXoZymes Inc.

Los Angeles-based eXoZymes Inc. (NASDAQ: 

), a pioneer of AI-enhanced enzymes that transform sustainable feedstock into nutraceuticals and new medicines, reported detailed downstream performance results from its recently completed 100-liter pilot production run of N-trans-caffeoyltyramine (NCT). 
 
eXoZymes Inc. is a B2i Digital Featured Company. See their full profile at 

. 
 
The company reports that the pilot run achieved approximately 99% reaction conversion, 91% process recovery, and a 90% isolated yield, resulting in 535 grams of isolated NCT at 99.6% pharma-grade purity. The production was executed by external partner Cayman Chemical, marking the first time the exozyme-based biomanufacturing process has been run end-to-end by an external partner, demonstrating protocol transferability and operational robustness. 
 
Co-founder of eXoZymes and VP of Development, Paul Opgenorth, PhD, noted: “What makes this initial NCT pilot run profound is how counter to conventional experience these results are. In most biological systems, performance typically degrades as you scale - reactions become harder to control, yields drop, and variability increases. With our AI-enhanced enzymes - exozymes - we see the opposite trend. At very small laboratory scale, where cell-free reactions are usually developed and optimized, performance can actually be the weakest. It improves at the one-liter scale, and this scaled run at 100 liters further reinforces that the system benefits from operating at larger volumes. Seeing that behavior carry through to high recovery, isolated yield, and pharma-grade purity supports that exozymes represent a fundamentally different and more scalable biomanufacturing paradigm compared to existing approaches.” 
 
Read the full news release at: 

 
 
eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. 
 
To learn more about eXoZymes Inc., visit 

/investor. 
 
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of 